The estimated Net Worth of Neil Gunn is at least $185 millier dollars as of 10 August 2024. Neil Gunn owns over 11,336 units of Neogenomics stock worth over $184,890 and over the last few years Neil sold NEO stock worth over $0.
Neil has made over 1 trades of the Neogenomics stock since 2024, according to the Form 4 filled with the SEC. Most recently Neil exercised 11,336 units of NEO stock worth $184,890 on 10 August 2024.
The largest trade Neil's ever made was exercising 11,336 units of Neogenomics stock on 10 August 2024 worth over $184,890. On average, Neil trades about 3,779 units every 0 days since 2023. As of 10 August 2024 Neil still owns at least 11,336 units of Neogenomics stock.
You can see the complete history of Neil Gunn stock trades at the bottom of the page.
Neil's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van et Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: